Cargando…

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag

Pretreatment blood counts, particularly an absolute reticulocyte count ≥25×10(9)/L, correlate with response to immunosuppressive therapy in severe aplastic anemia. In recent trials, eltrombopag combined with standard immunosuppressive therapy yielded superior responses than those to immunosuppressiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaimoku, Yoshitaka, Patel, Bhavisha A., Shalhoub, Ruba, Groarke, Emma M., Feng, Xingmin, Wu, Colin O., Young, Neal S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719075/ https://www.ncbi.nlm.nih.gov/pubmed/33910334 http://dx.doi.org/10.3324/haematol.2021.278413

Ejemplares similares

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

Deficit of circulating CD19(+)CD24(hi)CD38(hi) regulatory B cells in severe aplastic anaemia
por: Zaimoku, Yoshitaka, et al.
Publicado: (2020)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
por: Li, Ruixin, et al.
Publicado: (2022)

Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
por: Nakamura, Ryotaro, et al.
Publicado: (2023)

COVID‐19 infection in patients with severe aplastic anaemia
por: Paton, Casey, et al.
Publicado: (2021)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

Detectable mutations precede late myeloid neoplasia in aplastic anemia
por: Patel, Bhavisha A., et al.
Publicado: (2020)

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
por: Vicente, Alana, et al.
Publicado: (2020)

Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

P820: PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Li, R., et al.
Publicado: (2022)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
por: yang, B., et al.
Publicado: (2022)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
por: Tremblay, Gabriel, et al.
Publicado: (2019)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2023)

P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY
por: Aggarwal, N., et al.
Publicado: (2022)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
por: Liu, Limin, et al.
Publicado: (2022)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
por: Martynova, Anastasia, et al.
Publicado: (2021)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
por: Zhang, Senlin, et al.
Publicado: (2023)

Aplastic anemia: immunosuppressive therapy in 2010
por: Risitano, Antonio M., et al.
Publicado: (2011)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

S176: FUNCTIONAL AND ANTIGEN-SPECIFIC CHARACTERIZATION OF IMMUNE CELLS AT THE SINGLE-CELL LEVEL REVEALS CONVERGENCE OF ADAPTIVE AND INNATE IMMUNITY IN IMMUNE APLASTIC ANEMIA
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Immunosuppressive Treatment in Children with Acquired Aplastic Anemia
por: Yıldırmak, Yıldız, et al.
Publicado: (2012)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review
por: Yang, Yuan, et al.
Publicado: (2021)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
por: Kelly, Darren, et al.
Publicado: (2020)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia
por: Kelkka, Tiina, et al.
Publicado: (2022)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia
por: Lan, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fp04vtnjtn0q1tib4l7s8t33k1